CirculationPub Date : 2026-11-08DOI: 10.1161/CIRCULATIONAHA.126.083760
Stine Holmen, Olivier Manintveld, Kevin Damman, Ida Haugen Löfman, Mariusz Szymanski, Oscar Braun, Martin Lando, Elisabeth Bjørkelund, Jasper J Brugts, Yannick J H J Taverne, Jozine M Ter Maaten, Tonje Thorvaldsen, Michael Melin, Manon G van der Meer, Morten W Fagerland, Håvard Ravnestad, Einar Gude, Arne K Andreassen, Lars Gullestad, Kaspar Broch
{"title":"Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial.","authors":"Stine Holmen, Olivier Manintveld, Kevin Damman, Ida Haugen Löfman, Mariusz Szymanski, Oscar Braun, Martin Lando, Elisabeth Bjørkelund, Jasper J Brugts, Yannick J H J Taverne, Jozine M Ter Maaten, Tonje Thorvaldsen, Michael Melin, Manon G van der Meer, Morten W Fagerland, Håvard Ravnestad, Einar Gude, Arne K Andreassen, Lars Gullestad, Kaspar Broch","doi":"10.1161/CIRCULATIONAHA.126.083760","DOIUrl":"10.1161/CIRCULATIONAHA.126.083760","url":null,"abstract":"<p><strong>Background: </strong>Progressive kidney disease is common in heart transplant recipients due to calcineurin inhibitor exposure and pre-existing comorbidities. Sodium-glucose cotransporter-2 (SGLT2) inhibitors may attenuate the decline in kidney function, but evidence in heart transplant recipients is limited.</p><p><strong>Methods: </strong>The DAPAgliflozin for Renal protection in Heart Transplant recipients (DAPARHT) trial is a multicenter, double-blind, randomized, placebo-controlled trial conducted at six heart transplant centers in Northern Europe. We randomized adult heart transplant recipients with an estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m<sup>²</sup> at least one year after transplantation 1:1 to receive dapagliflozin 10 mg or matching placebo once daily. The primary endpoint was the slope of the eGFR from 2 weeks after treatment initiation to the end of the 12-month blinded treatment period.</p><p><strong>Results: </strong>Between June 2022 and September 2025, we randomized 430 participants, of whom 217 were allocated to dapagliflozin and 213 were allocated to placebo. We included the 424 patients with at least one eGFR measurement after baseline in the full analysis set. Their mean age was 53 ± 14 years and 29& were women. The eGFR at baseline was 67 ± 22 mL/min/1.73 m<sup>2</sup>. The median time from transplantation was 7 (3 - 13) years. Dapagliflozin improved the chronic slope of the eGFR compared with placebo. The change in the eGFR from 2 weeks to 12 months after treatment initiation was 2.0 (95% confidence interval [CI] 1.0 - 3.1) mL/min/1.73 m<sup>2</sup> in the dapagliflozin group and 0.3 (95% CI -0.8 - 1.4) mL/min/1.73 m<sup>2</sup> in the placebo group for a between-group difference of 1.7 (95% confidence interval 0.1 - 3.3) mL/min/1.73 m<sup>²</sup>; p = 0.03. There were no unexpected safety signals and similar rates of adverse events, including infections, between groups.</p><p><strong>Conclusions: </strong>In heart transplant recipients, dapagliflozin, compared with placebo, improved the slope of the eGFR from 2 weeks to 12 months of treatment.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-08DOI: 10.1161/CIRCULATIONAHA.126.084009
Gregory D Lewis, Nora K Horick, Fabely Moreno, Kenneth Lim, Diane Cocca-Spofford, Takenori Ikoma, Paridhi Gupta, Carly Camphausen, Laura Caccamo, Charounipha Soydara, Shaina McGinnis, Chloe Newlands, Skyler Williams, Alexandra Minasian, Nicholas Iskenderian, Isabela Landsteiner, Bhavani Iyer, Justin Joseph, Alvaro Delgado, Helena Tattersfield, Elizabeth Moore, Veronica Platt, Sujin Lee, Rajeev Malhotra
{"title":"Iron Repletion in Heart Failure With Preserved Ejection Fraction: The IRONMET-HFpEF Randomized Trial.","authors":"Gregory D Lewis, Nora K Horick, Fabely Moreno, Kenneth Lim, Diane Cocca-Spofford, Takenori Ikoma, Paridhi Gupta, Carly Camphausen, Laura Caccamo, Charounipha Soydara, Shaina McGinnis, Chloe Newlands, Skyler Williams, Alexandra Minasian, Nicholas Iskenderian, Isabela Landsteiner, Bhavani Iyer, Justin Joseph, Alvaro Delgado, Helena Tattersfield, Elizabeth Moore, Veronica Platt, Sujin Lee, Rajeev Malhotra","doi":"10.1161/CIRCULATIONAHA.126.084009","DOIUrl":"10.1161/CIRCULATIONAHA.126.084009","url":null,"abstract":"<p><strong>Background: </strong>Iron deficiency is present in >50% of patients with heart failure with preserved ejection fraction and is associated with reduced exercise capacity and survival. Whether iron repletion improves exercise capacity as objectively measured by peak oxygen uptake ([Formula: see text]) is unknown. The IRONMET-HFpEF trial (Impact of Intravenous Iron Repletion on Mechanisms of Exercise Intolerance in HFpEF) sought to determine whether ferric derisomaltose (FDI) compared with placebo improves peak [Formula: see text] in heart failure with preserved ejection fraction with iron deficiency.</p><p><strong>Methods: </strong>This was a double-blind, placebo-controlled randomized clinical trial of patients with heart failure with preserved ejection fraction and iron deficiency, defined as ferritin <100 ng/mL or <300 ng/mL with transferrin saturation <20%. Participants were enrolled between December 2021 and April 2026. Single-dose ferric derisomaltose (1000 mg; n=44) or placebo (n=21) was administered once intravenously. The primary end point was the change in peak [Formula: see text] from baseline to 12 weeks with an analysis of covariance model including terms for treatment group, baseline peak [Formula: see text], and sex. Secondary end points included changes in [Formula: see text] at the anaerobic threshold, 6-minute walk test distance, New York Heart Association class, health status assessed by the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score, and iron biomarkers at 12 weeks.</p><p><strong>Results: </strong>Among 65 randomized participants (median age, 68 years [interquartile range, 58-76 years], 72% women, transferrin saturation 16.0±7.4%, ferritin 57.8±48.9 ng/mL), 64 (98.5%) completed the study. The median baseline peak [Formula: see text] was 12.7 mL·kg<sup>-1</sup>·min<sup>-1</sup> (interquartile range, 10.6-15.8 mL·kg<sup>-1</sup>·min<sup>-1</sup>) in the FDI group and 12.2 mL·kg<sup>-1</sup>·min<sup>-1</sup> (11.6-14.6 mL·kg<sup>-1</sup>·min<sup>-1</sup>) in the placebo group. At 12 weeks, peak [Formula: see text] improved by 1.2 mL·kg<sup>-1</sup>·min<sup>-1</sup> (95% CI, 0.6-1.7) in the FDI group and was unchanged (0.1 mL·kg<sup>-1</sup>·min<sup>-1</sup> [95% CI, -0.7 to 0.9]) in the placebo group (least-squares mean difference, 1.1 mL·kg<sup>-1</sup>·min<sup>-1</sup> [95% CI, 0.2-1.9]; <i>P</i>=0.02). [Formula: see text] at the anaerobic threshold, 6-minute walk test distance, and New York Heart Association class also improved in the FDI compared with the placebo group (all <i>P</i><0.05), whereas the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score did not differ significantly between groups (FDI group, +4.4 [95% CI, -2.4 to 11.2]; <i>P</i>=0.20). FDI increased transferrin saturation (9.4% [95% CI, 4.9%-13.9%]) and ferritin (183 ng/mL [95% CI, 128-238]) compared with the placebo group (<i>P</i><sub>LSMD</sub><0.001 for both). There were no serious adverse events related to FDI admin","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-08DOI: 10.1161/CIRCULATIONAHA.126.084161
Monica Mukherjee, Harm-Jan Bogaard
{"title":"Against All Odds: A New CADENCE in Cardiopulmonary Remodeling.","authors":"Monica Mukherjee, Harm-Jan Bogaard","doi":"10.1161/CIRCULATIONAHA.126.084161","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.084161","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-08DOI: 10.1161/CIRCULATIONAHA.126.084111
Dalane W Kitzman, Robert J Mentz
{"title":"A Potential New Therapeutic Option for Exercise Intolerance in Patients with Heart Failure and Preserved Ejection Fraction.","authors":"Dalane W Kitzman, Robert J Mentz","doi":"10.1161/CIRCULATIONAHA.126.084111","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.084111","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-08DOI: 10.1161/CIRCULATIONAHA.126.084114
Marat Fudim, Andrew P Ambrosy
{"title":"Iron Repletion in HFpEF: An Endpoint Is Not Yet an Indication.","authors":"Marat Fudim, Andrew P Ambrosy","doi":"10.1161/CIRCULATIONAHA.126.084114","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.084114","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-08DOI: 10.1161/CIRCULATIONAHA.126.084065
Dilushi Wijayaratne, Richard Haynes
{"title":"Protecting the Kidneys After Replacing the Heart: Another Role for SGLT2 Inhibitors.","authors":"Dilushi Wijayaratne, Richard Haynes","doi":"10.1161/CIRCULATIONAHA.126.084065","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.084065","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-07DOI: 10.1161/CIRCULATIONAHA.126.083858
Sripal Bangalore, David J Maron, Rebecca Anthopolos, Harmony R Reynolds, Yifan Xu, Michelle Chang, Stephanie Boumakis, Jose Lopez-Sendon, Roxy Senior, Shaun G Goodman, Sean M O'Brien, Jerome L Fleg, Judith S Hochman
{"title":"Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in Patients With Advanced Chronic Kidney Disease: ISCHEMIA-CKD EXTEND.","authors":"Sripal Bangalore, David J Maron, Rebecca Anthopolos, Harmony R Reynolds, Yifan Xu, Michelle Chang, Stephanie Boumakis, Jose Lopez-Sendon, Roxy Senior, Shaun G Goodman, Sean M O'Brien, Jerome L Fleg, Judith S Hochman","doi":"10.1161/CIRCULATIONAHA.126.083858","DOIUrl":"10.1161/CIRCULATIONAHA.126.083858","url":null,"abstract":"<p><strong>Background: </strong>In the ISCHEMIA-CKD trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease), at a median follow-up of 2.2 years, the primary composite outcome of death or nonfatal myocardial infarction was similar between an initial invasive strategy (INV) compared with an initial conservative strategy (CON) in patients with moderate or severe myocardial ischemia and advanced chronic kidney disease. However, the long-term outcomes comparing the 2 strategies are unknown.</p><p><strong>Methods: </strong>Participants in the ISCHEMIA-CKD trial were randomly assigned to either INV, involving coronary angiography and revascularization when feasible, added to guideline-directed medical therapy or to CON with guideline-directed medical therapy alone and invasive procedures reserved for failure of guideline-directed medical therapy. After the active intervention trial phase, long-term vital status follow-up was conducted through participant contact by participating sites and by health record and centralized death database searches. The primary outcome for the extended follow-up phase was all-cause mortality. Secondary outcomes were cause-specific mortality, including cardiovascular and noncardiovascular mortality.</p><p><strong>Results: </strong>Among the 777 participants randomized (388 to INV and 389 to CON), over a median of 8 years of follow-up, vital status retention among survivors was 95%. There was a total of 429 deaths (55%). Cumulative all-cause mortality (57.4% versus 56.8%; adjusted hazard ratio, 1.05 [95% CI, 0.87-1.28]) or cardiovascular mortality (40.3% versus 38.4%; adjusted hazard ratio, 1.06 [95% CI, 0.84-1.34]) at 8 years did not differ between INV and CON. The restricted mean survival time was 1941 days (1834-2047 days) for INV versus 1990 days (1885-2094 days) for CON, with an adjusted estimated difference of -99 days (-245 to 46). The posterior probability of at least a 1 percentage point lower or higher death with INV at the 8-year median follow-up was 28% and 52%, respectively. Similarly, the posterior probability of at least a 1 percentage point lower or higher cardiovascular mortality with INV was 23% and 56%, respectively.</p><p><strong>Conclusions: </strong>In patients with at least moderate ischemia and advanced chronic kidney disease, there was no significant long-term benefit of an initial INV at reducing the risk of all-cause or cardiovascular mortality compared with an initial conservative strategy.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT01985360.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-07DOI: 10.1161/CIRCULATIONAHA.126.083999
Kenneth M Stein
{"title":"Data, Information, and Action: The Promises and Limits of AI-Enabled Electrocardiography.","authors":"Kenneth M Stein","doi":"10.1161/CIRCULATIONAHA.126.083999","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.083999","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-07DOI: 10.1161/CIRCULATIONAHA.126.083929
Zuzana Motovska, Oana Ionita, Marco Guglielmo, Milan Hromadka, Jan Baxa, Roberto Tarantini, Martin Kotrc, Roman Panovsky, Tobias Geisler, Martin Novak, Jiri Weichet, Dana Kautznerova, Petr Kuchynka, Tomas Ondrus, Gilles Montalescot, Jiri Jarkovsky, Jan Lhotsky, Nina Ajmone Marsan, Teodora Vichova, Petr Klofac, Andrea Andrasova, Robin Nijveldt, Monika Cani, Jan Precek, Libor Gajdusek, Martin Masek, Martin Penicka, Stanislav Bartus, Zbynek Tudos, Jiri Kettner, Ota Hlinomaz, Jan Belohlavek, Petr Kala, Pavol Tomasov, Deepak L Bhatt
{"title":"Multimodality Cardiac Imaging Substudy of the DAPT-SHOCK-AMI Randomized Trial: Echocardiographic and Cardiac Magnetic Resonance Assessment of Cangrelor versus Crushed Ticagrelor in Cardiogenic Shock Complicating Acute Myocardial Infarction.","authors":"Zuzana Motovska, Oana Ionita, Marco Guglielmo, Milan Hromadka, Jan Baxa, Roberto Tarantini, Martin Kotrc, Roman Panovsky, Tobias Geisler, Martin Novak, Jiri Weichet, Dana Kautznerova, Petr Kuchynka, Tomas Ondrus, Gilles Montalescot, Jiri Jarkovsky, Jan Lhotsky, Nina Ajmone Marsan, Teodora Vichova, Petr Klofac, Andrea Andrasova, Robin Nijveldt, Monika Cani, Jan Precek, Libor Gajdusek, Martin Masek, Martin Penicka, Stanislav Bartus, Zbynek Tudos, Jiri Kettner, Ota Hlinomaz, Jan Belohlavek, Petr Kala, Pavol Tomasov, Deepak L Bhatt","doi":"10.1161/CIRCULATIONAHA.126.083929","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.083929","url":null,"abstract":"<p><strong>Background: </strong>In acute myocardial infarction complicated by cardiogenic shock (AMI-CS), the myocardium sustains a dual injury: ischemia of the culprit territory and global hypoperfusion from low cardiac output. Whether platelet inhibition at reperfusion affects the microcirculation, the infarct, the noninfarcted myocardium, and ventricular function, and over what time course, has not been examined with serial imaging. The prespecified multimodality imaging substudy of the randomized DAPT-SHOCK-AMI trial (intravenous cangrelor versus crushed oral ticagrelor) addressed this question.</p><p><strong>Methods: </strong>Patients at prespecified imaging sites underwent serial echocardiography (208 enrolled; evaluable examinations in 175, 120, and 99 patients in the acute phase, at 1 month, and at 1 year) and cardiac magnetic resonance (CMR; 93 enrolled; 73, 68, and 63); 81 patients (40 and 41) underwent both modalities. Blinded core laboratories analyzed all studies. The primary imaging endpoint was microvascular obstruction (MVO) on acute CMR, evaluable in 60 patients; secondary endpoints were infarct size, native T1 of the global, infarcted, and remote myocardium, left ventricular (LV) ejection fraction (LVEF), global longitudinal strain (GLS), E/e', and left atrial volume, and their changes. Comparisons between the cangrelor and crushed ticagrelor arms used covariate-adjusted logistic or linear regression; the substudy was not separately powered.</p><p><strong>Results: </strong>The odds of acute MVO were lower with cangrelor (adjusted odds ratio 0.27 [95% CI 0.08 to 0.98]; P=0.023). Infarct size did not differ between the arms. At 1 year, native T1 of the remote myocardium was lower with cangrelor (adjusted mean 1114 [95% CI 1057 to 1171] versus 1171 [1115 to 1228] ms; P=0.005). Over 1 year, LVEF increased more with cangrelor on echocardiography (37.9% versus 21.7% of the acute value; adjusted P=0.046) and CMR (15.8% versus 2.1%; P=0.027), with greater improvement in GLS, lower E/e', and less left atrial enlargement; no parameter differed between the arms at 1 month.</p><p><strong>Conclusions: </strong>In AMI-CS, serial multimodality imaging characterized microvascular, tissue-level, and functional injury over 1 year. Cangrelor was associated with less acute MVO, lower remote native T1, and more complete recovery of LV function than crushed ticagrelor, without a difference in infarct size; these hypothesis-generating findings suggest differences in the microcirculation and non-infarcted myocardial injury but do not establish a treatment mechanism.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}